
PRODUCT INFORMATION

Leritrelvir

Item No. 46231



CAS Registry No.:	2923310-64-7
Formal Name:	(1S,3aR,6aS)-2-[(2S)-2-cyclohexyl-2-[(2,2,2-trifluoroacetyl) amino]acetyl]-N-[(1S)-3-(cyclopentylamino)-2,3-dioxo1-[[(3S)-2-oxo-3-pyrrolidinyl]methyl] propyl]octahydro-cyclopenta[c] pyrrole-1-carboxamide
Synonyms:	Leruiling, RAY1216
MF:	$C_{31}H_{44}F_3N_5O_6$
FW:	639.7
Purity:	≥95%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Leritrelvir is supplied as a solid. A stock solution may be made by dissolving the leritrelvir in the solvent of choice, which should be purged with an inert gas. Leritrelvir is slightly soluble (0.1-1 mg/ml) in acetonitrile and DMSO.

Description

Leritrelvir is an antiviral agent.[1,2] It inhibits the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M^{pro}) that is also known as the 3C-like protease ($3CL^{pro}$; K_i = 8.4 nM).[1] It reduces viral titers of seven SARS-CoV-2 variants (EC_{50}s = 69-135 nM plaque assays) and decreases lung viral titers, lung tissue inflammation injury, and lethality in a K18-hACE2 mouse model of SARS-CoV-2 infection. Leritrelvir inhibits replication of coxsackievirus B4 (CVB4) in HeLa cells (EC_{50} = 12.64 nM) and reduces viral replication, virus-induced organ lesions, and lethality in CVB4-infected mice at 12 mg/kg.[2]

References

1. Chen, X., Huang, X., Ma, Q., *et al*. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. *Nat. Microbiol.* **9(4)**, 1075-1088 (2024).
2. Liu, Q., Tang, B., Xuan, X., *et al*. The potential of leritrelvir repositioning for the treatment of coxsackievirus B4 and common enterovirus infections. *Antiviral Res.* **248**, 106367 (2026).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/10/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM